Centessa Pharmaceuticals (CNTA) Free Cash Flow (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Free Cash Flow of -$72.2 million for Q1 2026, down 26.16% year-over-year from -$97.8 million in Q1 2025, and down 29.39% quarter-over-quarter from -$55.8 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) Free Cash Flow (2020 - 2026) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 7 years of Free Cash Flow data on file, last reported at -$72.2 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$72.2 million, down 26.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$209.0 million (down 29.0% YoY), and the FY2025 annual result was -$194.2 million, down 36.67% from the prior year.
- Free Cash Flow eased to -$72.2 million in Q1 2026 per CNTA's latest filing, from -$55.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$21.4 million in Q3 2024 and troughed at -$72.2 million in Q1 2026.
- A 5-year average of -$45.3 million and a median of -$44.1 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow plunged 330.58% in 2022, then soared 44.67% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$52.2 million in 2022, then soared by 40.48% to -$31.1 million in 2023, then sank by 37.72% to -$42.8 million in 2024, then plunged by 30.42% to -$55.8 million in 2025, then dropped by 29.39% to -$72.2 million in 2026.
- Business Quant data shows CNTA's Free Cash Flow at -$72.2 million in Q1 2026, -$55.8 million in Q4 2025, and -$58.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Centessa Pharmaceuticals | 6.15 Bn | 6.15 Bn | - | -72.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.22 Mn |
| Mar 31, 2026 | -72.22 Mn |
| Dec 31, 2025 | -55.82 Mn |
| Dec 31, 2025 | -55.82 Mn |
| Sep 30, 2025 | -58.55 Mn |
| Sep 30, 2025 | -58.55 Mn |
| Jun 30, 2025 | -22.45 Mn |
| Jun 30, 2025 | -22.45 Mn |
| Mar 31, 2025 | -57.25 Mn |
| Mar 31, 2025 | -57.25 Mn |
| Dec 31, 2024 | -42.80 Mn |
| Dec 31, 2024 | -42.80 Mn |
| Sep 30, 2024 | -21.42 Mn |
| Sep 30, 2024 | -21.42 Mn |
| Jun 30, 2024 | -40.58 Mn |
| Jun 30, 2024 | -40.58 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Dec 31, 2023 | -31.08 Mn |
| Dec 31, 2023 | -31.08 Mn |